Ligand Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 285.7, 368.77, 433.7, 508.3, 609.43 ], "ebit_estimate": [ 136.57, 215.28, 281.75, 309.05, 389.13 ], "ebitda_estimate": [ 178.18, 271.3, 355.83, 414.01, 535.34 ], "net_income_estimate": [ 196.47, 253.35, 271.78, 284.7, 346.29 ], "per_share_eps_estimate": [ 4.25, 8.85, 10.93, 12.98, 14.86 ], "eps_nri_estimate": [ 8.97, 11.38, 13.65, 16.01, 17.52 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ 129.8, 233.52, 300.7, 231.2, null ], "operating_cash_flow_per_share_estimate": [ -3.64, 18.65, 11.5, 10.22, null ], "roa_estimate": [ 36.3, 47.8, null, null, null ], "roe_estimate": [ 19.53, 29.26, 24.53, null, null ], "gross_margin_estimate": [ 88.58, 89, 79, 94, 94 ], "operating_cash_flow_estimate": [ -72.37, 370.82, 228.66, 203.2, null ], "pettm_estimate": [ 74.34, 35.72, 28.93, 24.36, 21.28 ], "long_term_growth_rate_mean": 19.64, "long_term_revenue_growth_rate_mean": "18.51", "future_per_share_eps_estimate_growth": 27.99, "future_eps_nri_estimate_growth": 19.64, "future_revenue_estimate_growth": 18.51, "future_ebit_estimate_growth": 86.59, "future_ebitda_estimate_growth": 24.45, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 19.13, "future_pretax_income_estimate_growth": 28.4, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 14.5, "future_gross_margin_estimate_growth": -5.22, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 62.18, 79.6, 92.18, 75.61, 84.18, 90.7, 96.26 ], "ebit_estimate": [ 26.74, 42.13, 50.33, 36.41, 45.74, 52.29, 57.49 ], "ebitda_estimate": [ 38.77, 54.27, 60.35, 59.98, 69.43, 77.71, 84.16 ], "net_income_estimate": [ 41.18, 55.09, 65.72, 47.81, 55.38, 62, 67.17 ], "per_share_eps_estimate": [ 1.18, 1.67, 2.04, null, null, null, null ], "eps_nri_estimate": [ 2, 2.53, 2.84, 2.3, 2.65, 2.95, 3.18 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ 32.95, 45.95, 50.25, null, null, null, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ 26.59, 29.27, 17.76, null, null, null, null ], "gross_margin_estimate": [ 88.32, 88.64, 89.28, 96.1, 96.1, 96.1, 95.8 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ null, null, null, null, null, null, null ], "long_term_growth_rate_mean": 19.64, "long_term_revenue_growth_rate_mean": "18.51", "future_per_share_eps_estimate_growth": 27.99, "future_eps_nri_estimate_growth": 19.64, "future_revenue_estimate_growth": 18.51, "future_ebit_estimate_growth": 86.59, "future_ebitda_estimate_growth": 24.45, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 19.13, "future_pretax_income_estimate_growth": 28.4, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 14.5, "future_gross_margin_estimate_growth": -5.22, "future_operating_cash_flow_per_share_estimate_growth": null }